ÂÜÀòÂÒÂ×

Dr. Tunde Otulana joined Veloxis Pharmaceuticals as Chief Medical Officer in August 2020.

Before joining Veloxis, Dr. Otulana was Senior Vice President, Chief Medical Officer, at Mallinckrodt Pharmaceuticals from January 2016 to July 2020, where he had responsibility for global medical affairs, health economics and outcomes research, global pharmacovigilance, and medical communications.

Prior to Mallinckrodt, Dr. Otulana was Senior Vice President for Clinical Development and Medical Affairs (CDMA) at Boehringer Ingelheim Pharmaceutical from May 2013 to January 2016 and Vice President for Respiratory Therapeutic Area from December 2011 to May 2013. From 1998 to 2011, he held positions of increasing responsibility—from Vice President to Senior Vice President and Chief Medical Officer in the biotech industry in California, overseeing clinical development and operations, regulatory affairs, R&D, and toxicology. From 1991 to 1997, he served as Medical Officer and Clinical Team Leader in the Pulmonary & Allergy Drug Products Division at the FDA.

Dr. Otulana received his medical degree from the University of Ibadan, Ibadan, Nigeria. He completed his residency training in internal medicine at the University College Hospital, Ibadan, and fellowship in pulmonary medicine at Addenbrooke’s and Papworth Hospitals, University of Cambridge, UK, and at Howard University Hospital, Washington, DC.

Dr. Otulana is Clinical Professor of Pulmonary and Critical Care Medicine at the University of California, Davis Medical School as Volunteer Clinical Faculty. He also serves as Non-Executive Director on the Research, Education, and Innovation Board of Children’s National Hospital, Washington, DC.